MedTrace Logo

A Trial of LY3056480 in Patients With SNLH

NCT05061758 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-08-25

No results posted yet for this study

Summary

A phase 2 trial with LY3056480 in patients with stable SNHL

Conditions

  • Sensorineural Hearing Loss

Interventions

DRUG

LY3056480

LY3056480 is an inhibitor of gamma-secretase

Sponsors & Collaborators

  • Audion Therapeutics BV

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-09-30
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05061758 on ClinicalTrials.gov